Abstract

Almost 40% of patients with newly diagnosed small-cell lung cancer (SCLC) have disease confined to the ipsilateral hemithorax and within a single radiation port, ie, limited-stage disease. The median survival for this group of patients after treatment is approximately 15 months, with one in every four patients surviving 2 years. Current optimal treatment consists of chemotherapy with platinum/etoposide, given concurrently with thoracic radiation. Surgery may represent an option for very early-stage disease, but its added value is uncertain. Prophylactic cranial irradiation (PCI) is used for patients with limited-stage SCLC who have achieved a complete response following initial therapy, as it decreases the risk of brain metastases and provides an overall survival benefit. Newer targeted agents are currently being evaluated in this disease and hold the promise of improving current outcomes seen in patients with early-stage disease.

Original languageEnglish (US)
Pages (from-to)303-312
Number of pages10
JournalONCOLOGY
Volume21
Issue number3
StatePublished - Mar 1 2007

Fingerprint

Small Cell Lung Carcinoma
Radiation
Cranial Irradiation
Therapeutics
Survival
Etoposide
Platinum
Thorax
Neoplasm Metastasis
Drug Therapy
Brain

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Limited-stage small-cell lung cancer : Therapeutic options. / Ganti, Apar Kishor P; Zhen, Weining; Kessinger, Anne.

In: ONCOLOGY, Vol. 21, No. 3, 01.03.2007, p. 303-312.

Research output: Contribution to journalReview article

Ganti, AKP, Zhen, W & Kessinger, A 2007, 'Limited-stage small-cell lung cancer: Therapeutic options', ONCOLOGY, vol. 21, no. 3, pp. 303-312.
@article{6e968afbf5e4490ab1d65bf51753cd0d,
title = "Limited-stage small-cell lung cancer: Therapeutic options",
abstract = "Almost 40{\%} of patients with newly diagnosed small-cell lung cancer (SCLC) have disease confined to the ipsilateral hemithorax and within a single radiation port, ie, limited-stage disease. The median survival for this group of patients after treatment is approximately 15 months, with one in every four patients surviving 2 years. Current optimal treatment consists of chemotherapy with platinum/etoposide, given concurrently with thoracic radiation. Surgery may represent an option for very early-stage disease, but its added value is uncertain. Prophylactic cranial irradiation (PCI) is used for patients with limited-stage SCLC who have achieved a complete response following initial therapy, as it decreases the risk of brain metastases and provides an overall survival benefit. Newer targeted agents are currently being evaluated in this disease and hold the promise of improving current outcomes seen in patients with early-stage disease.",
author = "Ganti, {Apar Kishor P} and Weining Zhen and Anne Kessinger",
year = "2007",
month = "3",
day = "1",
language = "English (US)",
volume = "21",
pages = "303--312",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "3",

}

TY - JOUR

T1 - Limited-stage small-cell lung cancer

T2 - Therapeutic options

AU - Ganti, Apar Kishor P

AU - Zhen, Weining

AU - Kessinger, Anne

PY - 2007/3/1

Y1 - 2007/3/1

N2 - Almost 40% of patients with newly diagnosed small-cell lung cancer (SCLC) have disease confined to the ipsilateral hemithorax and within a single radiation port, ie, limited-stage disease. The median survival for this group of patients after treatment is approximately 15 months, with one in every four patients surviving 2 years. Current optimal treatment consists of chemotherapy with platinum/etoposide, given concurrently with thoracic radiation. Surgery may represent an option for very early-stage disease, but its added value is uncertain. Prophylactic cranial irradiation (PCI) is used for patients with limited-stage SCLC who have achieved a complete response following initial therapy, as it decreases the risk of brain metastases and provides an overall survival benefit. Newer targeted agents are currently being evaluated in this disease and hold the promise of improving current outcomes seen in patients with early-stage disease.

AB - Almost 40% of patients with newly diagnosed small-cell lung cancer (SCLC) have disease confined to the ipsilateral hemithorax and within a single radiation port, ie, limited-stage disease. The median survival for this group of patients after treatment is approximately 15 months, with one in every four patients surviving 2 years. Current optimal treatment consists of chemotherapy with platinum/etoposide, given concurrently with thoracic radiation. Surgery may represent an option for very early-stage disease, but its added value is uncertain. Prophylactic cranial irradiation (PCI) is used for patients with limited-stage SCLC who have achieved a complete response following initial therapy, as it decreases the risk of brain metastases and provides an overall survival benefit. Newer targeted agents are currently being evaluated in this disease and hold the promise of improving current outcomes seen in patients with early-stage disease.

UR - http://www.scopus.com/inward/record.url?scp=33947606783&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947606783&partnerID=8YFLogxK

M3 - Review article

VL - 21

SP - 303

EP - 312

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 3

ER -